Institut d'Investigació Biomèdica Sant Pau
The Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) is a CERCA center, acredited as Instituto de Investigación Sanitaria by the ISCIII and formed by entities: Fundació de Gestión Sanitaria del Hospital de la Santa Creu i Sant Pau (FGS-HSCSP), Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IR-HSCSP), Fundació Privada de l’Hospital de la Santa Creu i Sant Pau (FP-HSCSP), Universitat Autònoma de Barcelona (UAB), Fundació Puigvert (FP), Banc de Sang i Teixits (BST), Associació Col·laboració Centre Cochrane Iberoamericà (ACCIb), Equip d’Atenció Primària Sardenya (EAP Sardenya) and Agència de Salut Pública de Barcelona (ASPB), of which the IR-HSCSP is a management organ.


Its purpose is to promote, develop, manage and disseminate research and training in the field of health, mainly in the Campus Biomèdic Sant Pau and in collaboration with other institutions, promoting translational research that affects clinical activity, so that it is develop new techniques and processes that improve the quality of life of people.

Research in the IIB Sant Pau is carried out in 56 accredited and emerging research groups grouped in 7 areas of knowledge (Cardiovascular Diseases ; Genetic, Metabolic and Inflammatory Diseases ; Hematologic and Oncological Diseases ; Neurological, Mental Disorders and Ageing ; Uronephrology and Experimental Surgery ; Epidemiology, Public Health and Healthcare Services and Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment) and in 22 associated groups, which publish annually about a thousand articles in indexed journals and positioned in the first quartile of this subject matter in more than 50% of the cases.

Usage statistics Most popular
Latest additions:
2019-05-06
04:08
11 p, 1.2 MB Alzheimer's disease in Down syndrome : An overlooked population for prevention trials / Strydom, André (South London and Maudsley NHS Foundation Trust) ; Coppus, Antonia (Department of Primary and Community Care, Radboud University Medical Center, Nijmegen) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Danek, Adrian (Department of Neurology, Ludwig-Maximilians-Universität München) ; Fortea, Juan (Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down) ; Hardy, John (Reta Lila Weston Institute, Institute of Neurology, University College London) ; Levin, Johannes (German Center for Neurodegenerative Diseases (DZNE) site Munich) ; Nuebling, Georg (Department of Neurology, Ludwig-Maximilians-Universität München) ; Rebillat, Anne-Sophie (Institut Jérôme Lejeune) ; Ritchie, Craig (Centre for Clinical Brain Sciences. University of Edinburgh) ; van Duijn, Cornelia (Department of Epidemiology, Erasmus Medical Centre, Rotterdam) ; Zaman, Shahid (Cambridgeshire & Peterborough NHS Foundation Trust (CBFT), Fulbourn Hospital) ; Zetterberg, Henrik (Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital) ; Universitat Autònoma de Barcelona
The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. [...]
2018 - 10.1016/j.trci.2018.10.006
Alzheimer's & Dementia : Translational Research & Clinical Interventions, Vol. 4 (december 2018) , p. 703-713  
2019-05-06
04:08
41 p, 4.9 MB Effectiveness of Screening and Treatment Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from Endemic Countries in the EU/EEA : A Systematic Review / Agbata, Eric N. (Department of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain) ; Morton, Rachael L. (NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia; (R.L.M.); (A.T.); (N.R.)) ; Bisoffi, Zeno (Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy) ; Bottieau, Emmanuel (Department of Clinical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, 2000 Antwerp, Belgium) ; Greenaway, Christina (Division of Infectious Diseases and Clinical Epidemiology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, QC H3A 0G4, Canada) ; Biggs, Beverley-A. (Victorian Infectious Diseases Service, The Royal Melbourne Hospital RMH, Parkville VIC 3050, Australia) ; Montero, Nadia (Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito 170509, Ecuador; (N.M.); (I.A.-R.)) ; Tran, Anh (NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia; (R.L.M.); (A.T.); (N.R.)) ; Rowbotham, Nick (NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia; (R.L.M.); (A.T.); (N.R.)) ; Arevalo-Rodriguez, Ingrid (Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal (IRYCIS); CIBER Epidemiology and Public Health (CIBERESP), 28034 Madrid, Spain) ; Myran, Daniel T. (Bruyere Research Institute, University of Ottawa, Ottawa, ON K1N 6N5, Canada) ; Noori, Teymur (European Centre for Disease Prevention and Control, Gustav III: s Boulevard 40, 169 73 Solna, Sweden) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Pottie, Kevin (Centre for Global Health Institute of Population Health, University of Ottawa, Ottawa, ON K1N 6N5, Canada) ; Requena-Méndez, Ana (ISGlobal, Barcelona Institute for Global Health (ISGlobal-CRESIB, Hospital Clínic-University of Barcelona), E-08036 Barcelona, Spain)
We aimed to evaluate the evidence on screening and treatment for two parasitic infections—schistosomiasis and strongyloidiasis—among migrants from endemic countries arriving in the European Union and European Economic Area (EU/EEA). [...]
2018 - 10.3390/ijerph16010011
International Journal of Environmental Research and Public Health, Vol. 16 (december 2018)  
2019-04-04
13:08
11 p, 1.0 MB ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer / Cedó, Lidia (Institut d'Investigació Biomèdica Sant Pau) ; García León, Annabel (Institut d'Investigacions Biomèdiques Sant Pau) ; Baila Rueda, Lucía (Hospital Universitario Miguel Servet) ; Santos, David (Institut d'Investigacions Biomèdiques Sant Pau) ; Grijalva, Victor (University of California. Department of Medicine) ; Martínez Cignoni, Melanie Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Carbó, José María (Universitat de Barcelona) ; Metso, Jari (Minerva Foundation Institute for Medical Research) ; López Vilaró, Laura (Institut d'Investigacions Biomèdiques Sant Pau) ; Zorzano Olarte, Antonio (Institute for Research in Biomedicine) ; Valledor, Annabel F. (Universitat de Barcelona) ; Cenarro, Ana (Hospital Universitario Miguel Servet) ; Jauhiainen, Matti (Minerva Foundation Institute for Medical Research) ; Lerma Puertas, Enrique (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Fogelman, Alan M. (University of California. Department of Medicine) ; Reddy, Srinivasa T. (University of California. Department of Medicine) ; Escolà-Gil, Joan Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. [...]
2016 - 10.1038/srep36387
Scientific Reports, Vol. 6 (November 2016) , art. 36387  
2018-12-24
03:55
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony Servat, Jordi (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Cuatrecasas Freixas, Miriam ; Asensio, Elena (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Montironi, Carla (Hospital Clínic) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Marín Aguilera, Mercedes (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Horndler, Carlos (Hospital Miguel Servet) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic) ; Reig, Oscar (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Victoria, Iván (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Gaba, Lydia (Medical Oncology Department, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Universitat de Barcelona) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Miguel Servet) ; Escudero, Pilar (Hospital Clínico Universitatio Lozano Blesa) ; Fernández-Martos, Carlos (Instituto Valenciano de Oncología) ; Feliu, Jaime (Hospital La Paz, CIBERONC) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital de Móstoles) ; Gallego, Javier (Hospital de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova) ; Rojo, Federico (Pathology Department, Fundación Jiménez Diaz University) ; Castells, Antoni (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Prat, Aleix (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, Fisiologia i Immunologia) ; Maurel, Joan (Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS))
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
2018-11-01
22:41
From exome analysis in idiopathic azoospermia to the identification of a high-risk subgroup for occult Fanconi anemia / Krausz, Csilla (Institut d'Investigació Biomèdica Sant Pau) ; Riera-Escamilla, Antoni (Institut d'Investigació Biomèdica Sant Pau) ; Chianese, Chiara (Institut d'Investigació Biomèdica Sant Pau) ; Moreno-Mendoza, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Ars Criach, Elisabet (Institut d'Investigació Biomèdica Sant Pau) ; Rajmil, Osvaldo (Institut d'Investigació Biomèdica Sant Pau) ; Pujol i Calvet, M. Roser (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Bogliolo, Massimo (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ; Blanco, Ignacio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rodríguez, Inés (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Badell Serra, Isabel (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública) ; Ruiz-Castañé, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Surrallés i Calonge, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Purpose: in about 10% of patients affected by Fanconi anemia (FA) the diagnosis is delayed until adulthood, and the presenting symptom in these "occult" FA cases is often a solid cancer and cancer treatment-related toxicity. [...]
2019 - 10.1038/s41436-018-0037-1
Genetics in Medicine, Vol. 21, issue 1 (Jan. 2019) , p. 189-194  
2018-10-26
22:43
4 p, 7.9 MB Noves estratègies en el tractament del dolor : mecanisme d'acció d'un agonista cannabinoide durant el dolor inflamatori crònic / Negrete, Roger (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Hervera Abad, Arnau (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Leánez, Sergi (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Martín-Campos, Jesús M. (Institut d'Investigació Biomèdica Sant Pau. Grup de Bioquímica) ; Pol Rigau, Olga (Universitat Autònoma de Barcelona. Institut de Neurociències)
L’activació dels receptors cannabinoides, tant de tipus 1 (CB1) com de tipus 2 (CB2), exerceix potents efectes analgèsics en diferents models animals de dolor. L’analgèsia derivada d’agonistes dels receptors CB1 s’associa a diversos efectes secundaris, mentre que els agonistes selectius dels receptors CB2 alleugen el dolor sense causar tants efectes adversos. [...]
2011
Omnis cellula, Vol. 27 (2011) , p. 34-37  
2018-10-26
18:13
9 p, 1.2 MB Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy / Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ; Siles, Ana M (Institut d'Investigació Biomèdica Sant Pau) ; Alba-Rovira, Roser (Institut d'Investigació Biomèdica Sant Pau) ; Jáuregui, Agustín (Fundación Favaloro, Buenos, Aires, Argentina) ; Devaux, Jérôme (Aix-Marseille Université) ; Faivre-Sarrailh, Catherine (Aix-Marseille Université) ; Araque,Josefa (Institut d'Investigació Biomèdica Sant Pau) ; Rojas Garcia,Ricard (Institut d'Investigació Biomèdica Sant Pau) ; Diaz Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Cortés Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ; Nogales Gadea,Gisela (Institut Germans Trias i Pujol) ; Navas Madroñal, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Gallardo Vigo, Eduard (Institut d'Investigació Biomèdica Sant Pau) ; Illa, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. [...]
2017 - 10.1038/s41598-017-14853-4
Sientific reports, Vol. 7 (october 2017) , p. 1-9  
2018-10-05
18:23
18 p, 2.0 MB A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples / Esteve-Codina, Anna (Centre de Regulació Genòmica) ; Arpi, Oriol (Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)) ; Martinez-García, Maria (Hospital del Mar. Oncologia mèdica) ; Pineda, Estela (Hospital Clínic. Oncologia mèdica) ; Mallo, Mar (Institut Germans Trias i Pujol. Institut de Recerca Contra la Leucèmia Josep Carreras) ; Gut, Marta (Centre de Regulació Genòmica) ; Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rovira, Anna (Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)) ; Lopez, Raquel (Hospital Josep Trueta.) ; Tortosa, Avelina (Universitat de Barcelona, Departament d'Infermeria Fonamental) ; Dabad, Marc (Centre de Regulació Genòmica) ; Del Barco, Sonia (Institut Català d'Oncologia) ; Heath, Simon (Centre de Regulació Genòmica) ; Bagué, Silvia (Institut d'Investigació Biomèdica Sant Pau) ; Ribalta, Teresa (Hospital Clínic) ; Alameda, Francesc (Hospital del Mar) ; de la Iglesia, Nuria (Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS)) ; Balaña, Carmen (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ; on behalf of the GLIOCAT Group ; Glioma Catalonia Group (GLIOCAT) ; Universitat Autònoma de Barcelona
The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing platforms is rapidly becoming accepted as a tool for measuring gene expression for both research and clinical use. [...]
2017 - 10.1371/journal.pone.0170632
Plos one, 2017, p. 1-18  
2018-07-30
04:08
13 p, 787.1 KB Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease / Dekker, Alain D. (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Vermeiren, Yannick (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Carmona-Iragui, Maria (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Benejam, Bessy (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Videla, Laura (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Gelpi, Ellen (Neurological Tissue Bank—Biobanc, Hospital Clinic Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain) ; Aerts, Tony (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Van Dam, Debby (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Fernández, Susana (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; Lleó Bisa, Alberto (Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain) ; Videla, Sebastian (Faculty of Health and Life Sciences, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain) ; Sieben, Anne (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Martin, Jean-Jacques (Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain) ; De Deyn, Peter P. (Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium)
People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. [...]
2017 - 10.1016/j.dadm.2017.11.001
Alzheimer's Dementia : Diagnosis, Assessment Disease Monitoring, Vol. 10 (november 2017) , p. 99-111  
2018-06-18
04:06
23 p, 1.3 MB The behavioral and psychological symptoms of dementia in Down syndrome (BPSD-DS) scale : comprehensive assessment of psychopathology in Down syndrome / Dekker, Alain D. (Universitair Medisch Centrum Groningen) ; Sacco, Silvia (Institut Jérôme Lejeune) ; Carfi, Angelo (Universitá Cattolica del Sacro Cuore) ; Benejam, Bessy (Fundació Catalana Síndrome de Down) ; Vermeiren, Yannick (Universitair Medisch Centrum Groningen) ; Beugelsdijk, Gonny (Ipse de Bruggen) ; Schippers, Mieke (Ipse de Bruggen) ; Hassefras, Lyanne (Ipse de Bruggen) ; Eleveld, José (Cosis (Groningen)) ; Grefelman, Sharina (Cosis (Groningen)) ; Fopma, Roelie (Talant (Heerenveen)) ; Bomer-Veenboer, Monique (Pameijer (Rotterdam)) ; Boti, Mariángeles (Fundació Catalana Síndrome de Down) ; Oosterling, G. Danielle E. (Aveleijn (Borne)) ; Scholten, Esther (Elver (Nieuw-Wehl)) ; Tollenaere, Marleen (Institute Born-Bunge) ; Checkley, Laura (University College London. Division of Psychiatry) ; Strydom, André (University College London. Division of Psychiatry) ; Van Goethem, Gert (Het GielsBos (Gierle)) ; Onder, Graziano (Universitá Cattolica del Sacro Cuore) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; zu Eulenburg, Christine (Universitair Medisch Centrum Groningen) ; Coppus, Antonia M.W. (Dichterbij (Gennep)) ; Rebillat, Anne-Sophie (Institut Jérôme Lejeune) ; Fortea, Juan (Fundació Catalana Síndrome de Down) ; De Deyn, Peter P. (Universitair Medisch Centrum Groningen) ; Universitat Autònoma de Barcelona
People with Down syndrome (DS) are prone to develop Alzheimer's disease (AD). Behavioral and psychological symptoms of dementia (BPSD) are core features, but have not been comprehensively evaluated in DS. [...]
2018 - 10.3233/JAD-170920
Journal of Alzheimer's disease, Vol. 63, issue 2 (2018) , p. 797-819